NEXSEN BioTech Pty Ltd is thrilled to announce that it has successfully raised AUD 2,000,000 in its latest funding round, aimed at revolutionizing the way Group B Streptococcus (GBS) infections are diagnosed. GBS poses a significant health threat, particularly to newborns, with the CDC estimating that 2 to 3 in every 50 affected babies suffer dire consequences, and a staggering 5% fatality rate in serious cases among non-pregnant adults. To combat this pressing public health issue, NEXSEN BioTech is collaborating with leading researchers in Australia to develop an innovative rapid diagnostic tool specifically designed for GBS detection. This groundbreaking technology will empower healthcare providers to deliver swift and accurate screening results for pregnant women, ultimately enhancing maternal and neonatal health outcomes globally. Especially significant is the potential impact on underserved populations, where access to advanced pathology labs is limited鈥攖his tool will not only diagnose but also offer hope to countless families in regions that lack critical healthcare resources. With this new round of funding, NEXSEN BioTech is one step closer to closing the gap in GBS diagnosis and fostering safer pregnancies worldwide. The company remains dedicated to advancing medical technology that prioritizes patient safety, and this funding is an important step in making reliable diagnostic options accessible to all corners of the globe.





